v3.26.3
Investments, at Fair Value (Tables)
9 Months Ended
Sep. 30, 2026
Investments, at Fair Value [Abstract]  
Schedule of Fair Value Breakdown

The table below presents the fair value breakdown as of September 30, 2026:

 

    Tranche A Note     Tranche B Note     Total  
    Amount     Accrued
Interest
    Fair
Value
    Amount     Accrued
Interest
    Fair
Value
    Fair
Value
 
Notes   $ 7,675     $ 19,608     $ 18,716     $ 7,993     $ 20     $ 4,591     $ 23,307  
Warrants     -       -       -       207       -     $ 97     $ 97  
Royalty Purchase Agreement payment     -       -       -       -       -     $ 1,749     $ 1,749  
September 30, 2026                   $ 18,716               -     $ 6,437     $ 25,153  
Schedule of Assumptions and Estimates Value

The following table summarizes the assumptions and estimates used to value the Warrants as of September 30, 2026:

 

Parameters and Assumptions   Warrants  
Share Price   $ 4.45  
Conversion Rate     -  
Floor Rate     -  
Expected Term     3.02 – 3.21  
Volatility     69.04 – 69.54 %
Risk Free Rate     4.933 – 4.944 %
Yield     -  
Exercise Price   $ 20 – 36.40  
Dividend Rate     0 %
Schedule of Fair Value Composition

The table below represents the fair value composition of the Tranche B Note:

 

    September 30, 2026     December 31, 2025  
    Short term     Long term     Total     Short term     Long term     Total  
Tranche B Note   $ 4,591     $ -     $ 4,591     $ 11,473     $ -     $ 11,473  
Warrant   $ -     $ 97     $ 97     $ -     $ 850     $ 850  
Royalty Purchase Agreement   $ 944     $ 805     $ 1,749     $ 1,072     $ 1,137     $ 2,209  
Total   $ 5,535     $ 902     $ 6,437     $ 12,545     $ 1,987     $ 14,532  
Schedule of Scilex Transaction

The table below represents the fair value cycle of 2023 Scilex Transaction and 2024 Refinancing throughout December 31, 2025 and September 30, 2026:

 

    Tranche A     Tranche B     Total  
Balance as of December 31, 2024   $ 16,486     $ 18,322     $ 34,808  
Amounts receivable from the royalty agreement (*)     -       (1,640 )     (1,640 )
Principal payments     -       (9,875 )     (9,875 )
Proceeds from the sale of Subsequent Penny Warrants     (28,500 )     -       (28,500 )
Interest payments     -       (1,845 )     (1,845 )
Change in fair value     35,077       9,570       44,647  
Balance as of December 31, 2025     23,063       14,532       37,595  
Amounts receivable from the royalty agreement (*)     -       (1,118 )     (1,118 )
Principal payments     -       (7,132 )     (7,132 )
Interest payments     -       (764 )     (764 )
Change in fair value (**)     (4,347 )     919       (3,428 )
Balance as of September 30, 2026   $ 18,716     $ 6,437     $ 25,153  

 

(*) As of September 30, 2026 and December 31, 2025, $773 and $449, respectively, were included under prepaid expenses and other current assets.

 

(**) During the nine months ended September 30, 2026, the Company received an extension fee of $1,000 from Scilex in consideration for the extension of the maturity of the Tranche A Note and the Tranche B Note. The extension fee is presented separately within “Financial income, net” (see Note 15) and is not included in the change in fair value above. See “Developments during the nine months ended September 30, 2026” above.